ARNOLD C. HANISH - 20 Nov 2025 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
20 Nov 2025
Net transactions value
+$3,740
Form type
4
Filing time
24 Nov 2025, 17:08:13 UTC
Previous filing
01 Jul 2025
Next filing
02 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HANISH ARNOLD C Director C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON /s/Mark Rosenblum, as Attorney-in-Fact 24 Nov 2025 0001233253

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Purchase $3,740 +5,000 +33333% $0.7481 5,015 20 Nov 2025 By Arnold C. Hanish Trust F1
holding SLRX Common Stock 12 20 Nov 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75, inclusive. The reporting person undertakes to provide to Salarius Pharmaceuticals, Inc., any security holder of Salarius Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.